May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

May 27, 2025

New FDA approved Biosimilar Targets IL-12/23

The FDA has approved Starjemza, a ustekinumab biosimilar, for multiple inflammatory conditions.

Conexiant

May 22, 2025

New FDA-Approved Topical Foam for Scalp Psoriasis

The FDA has approved roflumilast (ZORYVE) foam 0.3% for once-daily treatment of plaque psoriasis in patients aged 12 and older, including hard-to-treat scalp and body areas..

Conexiant

May 22, 2025

Voices on the Go: Top Podcasts for Physicians

Physicians are tuning to podcasts that combine clinical insight, career development, and storytelling.

Conexiant

May 22, 2025

New AAP Guidelines Refresh Atopic Dermatitis Care

Applying topicals 2 to 3 times per week to previously affected areas—even when the skin appears clear—can reduce flare frequency and improve quality of life.

Conexiant

May 19, 2025

Zyrtec and Xyzal: FDA Issues Withdrawal Syndrome Warning

A new safety alert highlights the potential for severe itch following discontinuation of long-term cetirizine and levocetirizine use.

Conexiant

May 15, 2025

Assistant Professor Salary Gaps Persist Nationwide

Persistent salary disparities by gender, race, and ethnicity were identified among more than 45,000 U.S. assistant professors, with underrepresented in medicine women learning the least across all specialties.

Conexiant

May 14, 2025

Once-Daily Pill Helps Quell Eczema in Phase 3

Overall, safety findings were consistent with those of other approved JAK1 inhibitors.

Conexiant

May 09, 2025

Psoriasis: Icotrokinra Shows Promise in Late-Stage Trial

Icotrokinra is designed to block a protein, IL-23, involved in inflammatory responses.

Reuters